Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
In this episode of the Drug Solutions Podcast, Feliza Mirasol, Pharmaceutical Technology’s science editor, discusses technologies enabling biologics and emerging therapies manufacturing and development with Barry Holtz, PhD, chief scientific officer of Phylloceuticals, and Professor Yaakov Nahmias, founder and chief scientific officer, Tissue Dynamics and founder and president, Future Meat Technologies.
Resolving operational bottlenecks makes mAb manufacturing more efficient.
Inhalation formulations are complex, and empirical data are essential for realizing optimal solutions.
Advances in therapeutic modalities and an increase in molecular complexity have led to the need for an evolution in drug delivery approaches over the years.
Ongoing advances in technology and modeling techniques are helping to align all the objectives of both drug manufacturers and patients.
Using more exacting analytical tools can give a clearer assessment of gene-editing outcomes.
Digital maintenance solutions can help visualize the value and key activities provided by the equipment vendor from inception to utilization.
Recent trends in dissolution testing have led to increased use of data integrity solutions and more biorelevant testing techniques.
Partnering with an experienced service provider can help companies unlock the commercial potential of new therapeutic approaches.
Thermo Fisher Scientific has expanded its state-of-the-art R&D facility in Hyderabad, India.
GeoVax has received a patent for its malaria vaccine from the US Patent and Trademark Office.
Johnson & Johnson has launched its next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town.
The European Investment Bank has provided €15 million to fund coronavirus research at IRBM.
Otsuka Pharmaceutical and Osaka University have entered an exclusive license agreement on a new anti-tumor antibody.
In this episode of the Drug Solutions Podcast, Meg Rivers, senior editor, interviews Joy Aho, senior product manager at Be The Match BioTherapies, about sourcing autologous and allogeneic cell therapies.
AmoyDX has entered a Master Collaboration Agreement with AstraZeneca for multiple companion diagnostics programs in China, EU, and Japan.
ReiThera and Exothera are collaborating to develop a large-scale, low-cost-per-dose manufacturing process to deliver novel vaccines to low and middle-income countries.
Opus enters a strategic collaboration with Resilience for AAV-based gene therapy development and manufacturing for inherited retinal diseases.
Ymmunobio AG has signed a patent purchase agreement with LeukoCom GmbH to expand its development of cancer therapies.
IAVI and Moderna have announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health issues.
Evonetix’s thermally controlled DNA synthesis technology is designed to enable highly parallel DNA synthesis in a benchtop platform.
NIH has announced four new grant awards to fund new tuberculosis research advancement centers.
ATMPS Ltd has been granted a patent from the United States Patent and Trademark Office for the use of its Hataali blockchain technology used in personalized medicines.
Standardization is needed in CAR-T cell therapy development due to its inherent complexity.
Sterling Pharma Solutions has unveiled a £1 million expansion project to increase its capabilities and laboratories capacity at its Deeside, UK site.
